A-Ring Dihalogenation Increases the Cellular Activity of Combretastatin-Templated Tetrazoles
- 27 January 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 3 (3) , 177-181
Abstract
The combretastatins have been investigated for their antimitotic and antivascular properties, and it is widely postulated that a 3,4,5-trimethoxyaryl A-ring is essential to maintain potent activity. We have synthesized new tetrazole analogues (32–34), demonstrating that 3,5-dihalogenation can consistently increase potency by up to 5-fold when compared to the equivalent trimethoxy compound on human umbilical vein endothelial cells (HUVECs) and a range of cancer cells. Moreover, this increased potency offsets that lost by installing the tetrazole bridge into combretastatin A-4 (1), giving crystalline, soluble compounds that have low nanomolar activity, arrest cells in G2/M phase, and retain microtubule inhibitory activity. Molecular modeling has shown that optimized packing within the binding site resulting in increased Coulombic interaction may be responsible for this improved activity.Keywords
This publication has 25 references indexed in Scilit:
- Replacement of the double bond of antitubulin chalcones with triazoles and tetrazoles: Synthesis and biological evaluationBioorganic & Medicinal Chemistry Letters, 2011
- Microtubule-binding agents: a dynamic field of cancer therapeuticsNature Reviews Drug Discovery, 2010
- 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles That Are Cytotoxic against Combretastatin A Resistant Tumor Cells and Vascular Disrupting in a Cisplatin Resistant Germ Cell Tumor ModelJournal of Medicinal Chemistry, 2010
- Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4MedChemComm, 2010
- Advances in Synthetic Approaches for the Preparation of Combretastatin-Based Anti-Cancer AgentsSynthesis, 2009
- Anti‐mitotic activity of colchicine and the structural basis for its interaction with tubulinMedicinal Research Reviews, 2007
- Vascular disrupting agents in clinical developmentBritish Journal of Cancer, 2007
- Antineoplastic Agents. 509. Synthesis of Fluorcombstatin Phosphate and Related 3-Halostilbenes,1Journal of Natural Products, 2005
- Synthesis and evaluation of analogs of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agentsJournal of Medicinal Chemistry, 1992
- Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4Cellular and Molecular Life Sciences, 1989